Jun 26, 2018
Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research
Jun 12, 2018
Survey Finds Less than Two-Thirds of Americans (62%) Know a Preventive Vaccine is Available for Shingles
May 22, 2018
NanoViricides Files Quarterly Report for Period Ending March 31, 2018; Company Has Over A Year's Worth of Cash in Hand, and It Is Scaling Up Production of Certain Herpecide Program Drug Candidates
May 01, 2018
Lawsuit Alleges Widely-Used Shingles Vaccine Caused Permanent Loss of Eyesight
Apr 09, 2018
NanoViricides Reports Good Safety Profile of Topical Dermal Drug Candidates; Dr. Diwan, President, Will Present at the MicroCap Conference in New York City Today
Mar 27, 2018
Varicella Zoster Infection Treatment Market is Expected to Register a 4.2% CAGR From 2017 to 2027
Mar 19, 2018
NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the University of Wisconsin
Mar 16, 2018
CVS Pharmacy Now Offering New Shingles Vaccine at Locations Nationwide
Feb 22, 2018
Global Health Solutions to Pursue Orphan Indication Following Successful Preclinical Data for Ophthalmologic Drug Candidate
Feb 21, 2018
NanoViricides Files Quarterly Report for Period Ending December 31, 2017
Dec 06, 2017
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
Nov 20, 2017
NanoViricides Files Quarterly Report for Period Ending September 30, 2017
Nov 07, 2017
Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Nov 06, 2017
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
Oct 26, 2017
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
Oct 25, 2017
CDC's Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Oct 25, 2017
Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles
Oct 20, 2017
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Oct 20, 2017
FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant
Oct 17, 2017
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology